Trials / Completed
CompletedNCT00117182
Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD
A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (planned)
- Sponsor
- Syntara · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the Aridol (mannitol) challenge test can predict response to treatment with inhaled corticosteroids in COPD subjects. Subjects will undergo an Aridol test and then 3 months of treatment with inhaled corticosteroids. The effect on lung function and quality of life will then be measured and correlated with the Aridol test result.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dry powder mannitol | |
| DRUG | Budesonide 400mcg administered via turbuhaler | |
| DRUG | Ipratropium bromide 80mcg | |
| DRUG | Salbutamol 400mcg |
Timeline
- Start date
- 2005-07-01
- Completion
- 2006-08-01
- First posted
- 2005-07-04
- Last updated
- 2016-04-20
Locations
13 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00117182. Inclusion in this directory is not an endorsement.